Abstract
Malignancy is a major cause of death in patients with inflammatory disease. The risk of individual malignancies is altered in some inflammatory diseases, such as rheumatoid arthritis and psoriasis. This study aimed to examine malignancy incidence in patients with psoriatic arthritis (PsA), a related inflammatory disease. Institutional cancer registry and medical record linkage systems were retrospectively reviewed in a population-based incidence cohort of 217 patients with PsA and 434 age- and sex-matched comparators. Malignancy rates were compared using adjusted Cox models. Incidence of overall malignancy (excluding NMSC; hazard ratio (HR) 1.64; 95 % confidence interval (CI) 1.03–2.61) and breast cancer (HR 3.59; 95 % CI 1.22–10.61), but not NMSC (HR 1.23; 95 % CI 0.72–2.09), were significantly elevated in the PsA cohort. Age and female sex were similar predisposing risk factors in both cohorts. The overall incidence of malignancy, as well as the risk of breast cancer, was higher in patients with PsA than in the general population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740–1751. doi:10.1002/art.20311
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 17:212. doi:10.1186/s13075-015-0728-9
Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB (2006) The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126(10):2194–2201. doi:10.1038/sj.jid.5700410
Frentz G, Olsen JH (1999) Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140(2):237–242
Gladman DD (2008) Mortality in psoriatic arthritis. Clin Exp Rheumatol 26(5 Suppl 51):S62–S65
St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Rocca WA (2011) Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol 173(9):1059–1068. doi:10.1093/aje/kwq482
Ernste FC, Sanchez-Menendez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H (2015) Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 67(7):1015–1021. doi:10.1002/acr.22536
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 36(2):361–367. doi:10.3899/jrheum.080691
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. doi:10.1002/art.21972
Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695–706
Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD (2008) Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58(1):82–87. doi:10.1002/art.23185
Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J (2014) Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 66(5):1282–1290. doi:10.1002/art.38339
Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64(6):1035–1050. doi:10.1016/j.jaad.2010.09.734
Fanto M, Peragallo MS, Pietrosanti M, Di Rosa R, Picchianti Diamanti A, Salemi S, D'Amelio R (2016) Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience. Intern Emerg Med 11(1):31–40. doi:10.1007/s11739-015-1270-0
Acknowledgments
This publication was made possible by the Rochester Epidemiology Project (R01 AG 034676 from the National Institutes of Health) and the CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). KMW was supported by the National Institutes of General Medical Sciences (grant T32-GM-65841) and the Mayo Clinic College of Medicine’s Medical Scientist Training Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Wilton, K.M., Crowson, C.S. & Matteson, E.L. Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study. Clin Rheumatol 35, 2603–2607 (2016). https://doi.org/10.1007/s10067-016-3396-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-016-3396-5